Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.1
(-2.36%)
SEK 3.1
(-2.36%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 87.07 Million SEK | -60.16% |
| 2022 | 218.56 Million SEK | -34.46% |
| 2021 | 333.49 Million SEK | 30.59% |
| 2020 | 255.37 Million SEK | 2.06% |
| 2019 | 250.22 Million SEK | -12.94% |
| 2018 | 287.42 Million SEK | 147.46% |
| 2017 | 116.14 Million SEK | 44.48% |
| 2016 | 80.39 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 92.12 Million SEK | 5.8% |
| 2024 Q2 | 94.95 Million SEK | 3.07% |
| 2023 Q2 | 139.29 Million SEK | -22.73% |
| 2023 FY | 87.07 Million SEK | -60.16% |
| 2023 Q4 | 87.07 Million SEK | -18.14% |
| 2023 Q3 | 106.36 Million SEK | -23.64% |
| 2023 Q1 | 180.28 Million SEK | -17.52% |
| 2022 FY | 218.56 Million SEK | -34.46% |
| 2022 Q4 | 218.56 Million SEK | -13.98% |
| 2022 Q3 | 254.09 Million SEK | -10.24% |
| 2022 Q2 | 283.08 Million SEK | -7.94% |
| 2022 Q1 | 307.5 Million SEK | -7.79% |
| 2021 Q2 | 389.72 Million SEK | -11.03% |
| 2021 Q1 | 438.03 Million SEK | 71.53% |
| 2021 Q3 | 365.04 Million SEK | -6.33% |
| 2021 Q4 | 333.49 Million SEK | -8.64% |
| 2021 FY | 333.49 Million SEK | 30.59% |
| 2020 FY | 255.37 Million SEK | 2.06% |
| 2020 Q2 | 309.27 Million SEK | 30.95% |
| 2020 Q1 | 236.17 Million SEK | -5.62% |
| 2020 Q3 | 288.95 Million SEK | -6.57% |
| 2020 Q4 | 255.37 Million SEK | -11.62% |
| 2019 Q4 | 250.22 Million SEK | -8.37% |
| 2019 FY | 250.22 Million SEK | -12.94% |
| 2019 Q2 | 287.42 Million SEK | 2.96% |
| 2019 Q1 | 279.15 Million SEK | 164.7% |
| 2019 Q3 | 273.08 Million SEK | -4.99% |
| 2018 Q2 | 116.14 Million SEK | 0.0% |
| 2018 Q4 | 105.46 Million SEK | 0.0% |
| 2018 FY | 287.42 Million SEK | 147.46% |
| 2017 FY | 116.14 Million SEK | 44.48% |
| 2016 FY | 80.39 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 26.491% |
| Ziccum AB (publ) | 14.97 Million SEK | -481.566% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -334.469% |
| BioArctic AB (publ) | 1.18 Billion SEK | 92.659% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -39.59% |
| Mendus AB (publ) | 755.95 Million SEK | 88.482% |
| Genovis AB (publ.) | 288.85 Million SEK | 69.856% |
| Intervacc AB (publ) | 259.61 Million SEK | 66.461% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -107.517% |
| Active Biotech AB (publ) | 44 Million SEK | -97.891% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 68.763% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -40.095% |
| Aptahem AB (publ) | 63.02 Million SEK | -38.155% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 82.454% |
| Kancera AB (publ) | 65.64 Million SEK | -32.645% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 75.217% |
| Fluicell AB (publ) | 9.34 Million SEK | -832.248% |
| Saniona AB (publ) | 64.14 Million SEK | -35.747% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -159.127% |
| Biovica International AB (publ) | 131.4 Million SEK | 33.739% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -64.333% |
| AcouSort AB (publ) | 34.51 Million SEK | -152.288% |
| Xintela AB (publ) | 18.39 Million SEK | -373.346% |
| Abliva AB (publ) | 87.49 Million SEK | 0.488% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 88.546% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 93.081% |
| OncoZenge AB (publ) | 20.34 Million SEK | -328.083% |
| Amniotics AB (publ) | 26.08 Million SEK | -233.788% |
| 2cureX AB (publ) | 16.62 Million SEK | -423.741% |
| CombiGene AB (publ) | 120.61 Million SEK | 27.808% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1332.812% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 95.419% |
| Camurus AB (publ) | 1.9 Billion SEK | 95.436% |
| Corline Biomedical AB | 100.1 Million SEK | 13.019% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 50.84% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 38.07% |
| I-Tech AB | 152.44 Million SEK | 42.882% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 91.447% |
| Cyxone AB (publ) | 43.65 Million SEK | -99.455% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -10.649% |
| Biosergen AB | 7.2 Million SEK | -1109.165% |
| Cantargia AB (publ) | 223.71 Million SEK | 61.079% |
| NextCell Pharma AB | 81.28 Million SEK | -7.115% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 88.622% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -188.576% |
| Nanologica AB (publ) | 77.42 Million SEK | -12.454% |
| SynAct Pharma AB | 228.01 Million SEK | 61.814% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -225.345% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -301.2% |
| LIDDS AB (publ) | 17.65 Million SEK | -393.186% |
| Lipum AB (publ) | 12.11 Million SEK | -619.009% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 93.781% |
| Alzinova AB (publ) | 123.18 Million SEK | 29.318% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 63.473% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -929.829% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -2.165% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -485.594% |
| Simris Alg AB (publ) | 174.55 Million SEK | 50.117% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 59.882% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 86.676% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -205.43% |